Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Active, not recruiting · NCT03308396 · Registry updated 2022-02-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2022-02-17 | NCT03308396 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ajjai Alva, MD | 1 |
| AstraZeneca | 806 |
| Big Ten Cancer Research Consortium | 2 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Penn State Cancer Institute | Hershey | United States | 17 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |
| Univerisity of Illinois Cancer Center | Chicago | United States | 1 |
| University of Iowa Hosptials and Clinics | Iowa City | United States | 1 |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | United States | 88 |